In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates-Reference-Cited by-同舟云学术

In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates

Published:2023-10 Issue:4 Volume:62 Page:106938
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Burke Andrew^ORCID,Carter Robyn^ORCID,Tolson Carla,Congdon Jacob,Duplancic Christine,Bursle Evan^ORCID,Bell Scott C.^ORCID,Roberts Jason A.^ORCID,Thomson Rachel^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference31 articles.

1. The rise of non-tuberculosis mycobacterial lung disease;Ratnatunga;Front Immunol,2020

2. Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010–2014;Adjemian;Ann Am Thorac Soc,2018

3. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline;Daley;Clin Infect Dis,2020

4. Dissecting erm [41]-mediated macrolide-inducible resistance in Mycobacterium abscessus;Richard;Antimicrob Agents Chemother,2020

5. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study;Jhun;European Respir J,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection;Cureus;2024-07-22

2. In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus;Antimicrobial Agents and Chemotherapy;2024-05-02

3. It takes two to tango! Stability of drugs affecting efficacy against Mycobacterium abscessus;International Journal of Antimicrobial Agents;2024-02